ERBB2 and breast cancer: Administration of the nanoliposomes conjugated with a long multi-epitope peptide derived from HER2/neu and a Pan HLA-DR epitope (PADRE) peptide improves CTL responses, and subsequently causing significant inhibition of tumor growth and metastasis in HER2+ TUBO mammary tumor-bearing mice [70].